Prospective clinical study for Yuyang Capsule combined with HAART intervention in HIV-infected patients

Prospective clinical study for Yuyang Capsule combined with HAART to promote immune reconstitution and delay of AIDS period based on thought of

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002404

Enrollment

Unknown

Registered

2019-06-15

Start date

2019-06-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

control group:oral placebo combined with HAART drugs

experimental group :oral Yuyang capsule combined with HAART drugs

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. HIV-infected patients who meet the diagnostic criteria of the Third Edition of HIV/AIDS Guidelines (2015 Edition); 3. Baseline CD4 cell count >=200/ul; 4. Start HAART time >=6 months; 5. Good Compliance; 6. Those who are willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. combined with opportunistic infections and other complications appear; 2. merger severe cardiovascular and cerebrovascular, liver, kidney and hematopoietic diseases; 3. psychiatric patients; 4. pregnant and lactating women; 5. receiving other treatments that may affect the efficacy of the test drug.

Design outcomes

Primary

Measure	Time frame
CD4+T lymphocytes;CD4+CD25+CD127low;CD8+T lymphocytes;CD8+CD38+HLA-DR+;CD4+CD38+HLA-DR+;	—

Secondary

Measure	Time frame
HIV viral-load;	—

Countries

China

Contacts

Public ContactPeng Xin

Sichuan Academy of Traditional Chinese Medicine

pxtcm1001@yeah.net+86 13980929872

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026